AlphaMol
AlphaMol attracts leading scientists in the areas of both biological computing
and pharmaceutical sciences to join the team. We develop cutting-edge
bio-technologies to substantially speed up modern drug discovery. We aim
at challenging essential diseases in human health.
AlphaMol has sites in Basel in Switzerland as well as in Shanghai and Shenzhen in China.
AlphaMol has four major departments in research including:
computational drug discovery, medicinal chemistry, cell biology & biochemistry as well as pharmacology.
CO-FOUNDERS
Dr.Shuguang Yuan
Co-Founder
Dr. Shuguang Yuan is a leading scientist in GPCR biology and computational drug discovery, with extensive experience spanning both academia and the pharmaceutical industry. He received his Ph.D. through the prestigious Marie Curie program, conducting research across École Polytechnique Fédérale de Lausanne, Polish Academy of Sciences, and KU Leuven, where his thesis was recognized with distinction. He later held a Marie Curie postdoctoral fellowship at ETH Zurich and subsequently gained several years of industrial experience from the GPCR drug development company Actelion in Basel, Switzerland.

Dr. Yuan’s research focuses on the molecular mechanisms of G protein–coupled receptors (GPCRs), with more than 17 years of research experience in this area, integrating structural biology and artificial intelligence–driven drug discovery. He is among the early contributors to the mechanistic understanding of GPCR activation, including the proposal of a continuous water channel model, which has helped guide rational agonist and antagonist design.

During his time in the pharmaceutical industry in Basel, Dr. Yuan played a key role in advancing two GPCR-targeted drug candidates into clinical development. Notably, one of these programs ultimately received approval from the U.S. Food and Drug Administration, while the other has progressed into Phase II clinical trials, demonstrating his ability to translate cutting-edge science into impactful therapeutic outcomes.

He has published over 100 peer-reviewed articles and is consistently recognized among the Global Top 2% Scientists since 2022. His work has achieved an h-index of 39, reflecting both productivity and scientific impact.

Dr. Yuan is the founder of AlphaMol, where he leads the development of an advanced AI-driven platform for GPCR-targeted drug discovery, aiming to accelerate the creation of first-in-class therapeutics in areas of high unmet medical need.
Dr.Horst Vogel
Co-Founder
Prof. Horst Vogel is a distinguished biophysicist and a leading expert in membrane protein science, with more than 40 years of research experience in G protein–coupled receptors (GPCRs). He is a full professor at École Polytechnique Fédérale de Lausanne, where he has made seminal contributions to the understanding of receptor structure, dynamics, and signaling mechanisms at the molecular level.

Prof. Vogel’s research integrates biophysics, structural biology, and advanced imaging technologies to elucidate how membrane proteins function in complex biological systems. His work has significantly advanced GPCR research, particularly in uncovering receptor conformational dynamics and activation mechanisms, providing a strong foundation for structure-based drug discovery.

He is a member of the Swiss Academy of Sciences and the National Academy of Inventors, and has been consistently recognized among the Global Top 2% Scientists for many years. Prof. Vogel has an h-index of 82 and has received more than 25,000 citations, reflecting his outstanding and sustained scientific impact.

In addition, he has served as a member of the Nobel Prize nomination committee and as an expert evaluator for the European Union’s Seventh Framework Programme (FP7), highlighting his international recognition and influence in the scientific community.

Prof. Vogel has also maintained long-standing collaborations with leading global companies, including Roche, Novartis, and Nestlé, contributing to the translation of fundamental research into industrial and therapeutic applications.

As a respected scientific leader, Prof. Vogel has mentored numerous researchers and continues to drive interdisciplinary innovation at the interface of biology, physics, and chemistry.